KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Interest & Investment Income (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Interest & Investment Income for 16 consecutive years, with $19.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income rose 8.65% year-over-year to $19.2 million, compared with a TTM value of $74.9 million through Dec 2025, changed 0.03%, and an annual FY2025 reading of $74.9 million, changed 0.03% over the prior year.
  • Interest & Investment Income was $19.2 million for Q4 2025 at Biomarin Pharmaceutical, up from $17.9 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $19.8 million in Q2 2024 and bottomed at $1.7 million in Q4 2021.
  • Average Interest & Investment Income over 5 years is $11.8 million, with a median of $14.2 million recorded in 2023.
  • The sharpest move saw Interest & Investment Income plummeted 54.37% in 2021, then skyrocketed 556.21% in 2023.
  • Year by year, Interest & Investment Income stood at $1.7 million in 2021, then soared by 399.14% to $8.7 million in 2022, then surged by 107.16% to $18.0 million in 2023, then dropped by 2.02% to $17.7 million in 2024, then rose by 8.65% to $19.2 million in 2025.
  • Business Quant data shows Interest & Investment Income for BMRN at $19.2 million in Q4 2025, $17.9 million in Q3 2025, and $18.8 million in Q2 2025.